News | March 30, 2026
Sun Pharma to spotlight 14 dermatology studies at 2026 AAD annual meeting
The presentations underscore the company’s deep expertise in dermatology and immunology
The presentations underscore the company’s deep expertise in dermatology and immunology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone
The programme aims to provide critical healthcare services to approximately 4 lakh people in remote and resource-scarce communities
As Tracky launches integrated health solution
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
Call it a major breakthrough for diagnostic imaging
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
Subscribe To Our Newsletter & Stay Updated
